Complicazioni della chemioterapia

  • Alessandra Erbetta
  • Giuseppe Lauria
  • Angelo Sghirlanzoni


Sono circa 3.500.000 nel mondo occidentale i pazienti annualmente sottoposti a chemioterapia con composti la cui tossicità è dose-limitante per il sistema nervoso centrale (SNC) e per il periferico (SNP).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Keime-Guibert F, Napolitano M, Delattre JY (1998) Neurological complications of radiotherapy and chemotherapy. J Neurol 245:695–708PubMedCrossRefGoogle Scholar
  2. 2.
    Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17PubMedCrossRefGoogle Scholar
  3. 3.
    Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549–1563PubMedCrossRefGoogle Scholar
  4. 4.
    Sghirlanzoni A, Pareyson D, Lauria G (2005) Sensory neuron diseases. Lancet Neurol 4:349–361PubMedCrossRefGoogle Scholar
  5. 5.
    Peltier AC, Russell JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol 15:633–638PubMedCrossRefGoogle Scholar
  6. 6.
    Guthrie TH Jr, Gynther L (1985) Acute deafness. A complication of high-dose cisplatin. Arch Otolaryngol 111:344–345PubMedGoogle Scholar
  7. 7.
    Isoardo G, Bergui M, Durelli L, Barbero P, Boccadoro M, Bertola A, Ciaramitaro P, Palumbo A, Bergamasco B, Cocito D (2004) Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 109:188–193PubMedCrossRefGoogle Scholar
  8. 8.
    Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G (1998) Cispatin neurotoxicity presenting as reversible posterior leucoencephalopathy syndrome. AJNR Am J Neuroradiol 19:415–417PubMedGoogle Scholar
  9. 9.
    Philip PA, Carmichael J, Harris AL (1991) Convulsions and transient cortical blindness after cisplatin. BMJ 302:416PubMedGoogle Scholar
  10. 10.
    Rangi PS, Partridge WJ, Newlands ES, Waldman AD (2005) Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology 47:586–590PubMedCrossRefGoogle Scholar
  11. 11.
    Verschraegen C, Conrad CA, Hong WK (1995) Subacute encephalopathy toxicity of cisplatin. Lung Cancer 13:305–309PubMedCrossRefGoogle Scholar
  12. 12.
    Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478–3483PubMedCrossRefGoogle Scholar
  13. 13.
    Caraceni A, Martini C, Spatti G et al (1997) Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurologica Scandinavica 96:260–261PubMedCrossRefGoogle Scholar
  14. 14.
    Pace A, Savarese A, Picardo M et al (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21:927–931PubMedCrossRefGoogle Scholar
  15. 15.
    Argyriou AA, Polychronopoulos P, Iconomou G et al (2005) Paclitaxel plus carboplatin-induced peripheral neuropathy A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252:1459–1464PubMedCrossRefGoogle Scholar
  16. 16.
    Bargallò N, Burrel M, Berenguer J, Cofan F, Bunesch L, Mercader M (2000) Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. AJNR Am J Neuroradiol 21:479–484PubMedGoogle Scholar
  17. 17.
    Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115–118PubMedGoogle Scholar
  18. 18.
    Mita C, Chatelut E, Bekradda M, Soulie P, Canal P, Misset JL, Cvitkovic E, Bugat R (2003) Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies. Ann Oncol 14:1776–1782PubMedCrossRefGoogle Scholar
  19. 19.
    Ziske CG, Schottker B, Gorschluter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbrucher T, Schmidt-Wolf IGH (2002) Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 13:629–631PubMedCrossRefGoogle Scholar
  20. 20.
    Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Baron A, Jones RB (1999) Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 5:501–506PubMedGoogle Scholar
  21. 21.
    Plotkin SR, Wen PY (2003) Neurologic complications of cancer therapy. Neurol Clin 21:279–318PubMedCrossRefGoogle Scholar
  22. 22.
    Scaioli V, Caraceni A, Martini C, Curzi S, Capri G, Luca G (2005) Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neurooncol 25:1–9Google Scholar
  23. 23.
    van Laarhoven HW, Verstappen CC, Beex LV, Kappelle AC, Punt CJ (2003) 5-FU-induced peripheral neuropathy: a rare complication of a well-known drug. Anticancer Res 23:647–648PubMedGoogle Scholar
  24. 24.
    Heier MS, Fossa SD (1986) Wernicke-Korsakoff-like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5’-dFUrd). Acta Neurol Scand 73:449–457PubMedCrossRefGoogle Scholar
  25. 25.
    Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, Rivera GK, Thompson SJ, Evans WE, Pui CH (1998) Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 12:1176–1181PubMedCrossRefGoogle Scholar
  26. 26.
    Rollins N, Winick N, Bash R, Booth T (2004) Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 25:1688–1695PubMedGoogle Scholar
  27. 27.
    Fisher JM, Khademian ZP, Simon EM, Zimmerman RA, Bilaniuk LT (2005) Diffusion-weighted MR imaging of the early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 26:1686–1689PubMedGoogle Scholar
  28. 28.
    Gagliano RG, Costanzi JJ (1976) Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 37:1663–1668PubMedCrossRefGoogle Scholar
  29. 29.
    Packer RJ, Sposto R, Atkins TE, Sutton LN, Bruce DA, Siegel KR, Rorke LB, Littman PA, Schut L (1987) Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatr Neurosci 13:169–175PubMedGoogle Scholar
  30. 30.
    Cho SG, Moon H, Lee JH, Lee SY, Kim CC, Lee KS (1999) Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenenous leukemia. J Korean Med Sci 14:89–92PubMedGoogle Scholar
  31. 31.
    Vogel H, Horoupian DS (1993) Filamentous degeneration of neurons. A possible feature of cytosine arabinoside neurotoxicity. Cancer 71:1303–1308PubMedCrossRefGoogle Scholar
  32. 32.
    Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X (2004) Anticancer Drugs 15:347–350PubMedCrossRefGoogle Scholar
  33. 33.
    Wengs WJ, Talwar D, Bernard J (1993) Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 50:1104–1105PubMedGoogle Scholar
  34. 34.
    Meyer T, Ludolph AC, Munch C (2002) Ifosfamide encephalopathy presenting with asterixis. J Neurol Sci 199:85–88PubMedCrossRefGoogle Scholar
  35. 35.
    Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB (2000) Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 82:291–294PubMedCrossRefGoogle Scholar
  36. 36.
    Rosenblum MK, Delattre JY, Walker RW, Shapiro WR (1989) Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 7:269–281PubMedCrossRefGoogle Scholar
  37. 37.
    Omuro AMP, De Angelis LM, Yahalom J, Abrey LE (2005) Chemotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64:69–74PubMedCrossRefGoogle Scholar
  38. 38.
    Adkins JC, Peters DH, Markham A (1997) Fludarabine An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005–1037PubMedGoogle Scholar
  39. 39.
    Cheson BD, Vena DA, Foss FM (1994) Neurotoxicity of purine analogs: a review. J Clin oncol 12:2216–2228PubMedGoogle Scholar
  40. 40.
    Athale UH, Chan AKC (2003) Thrombosis in children with acute lymphoblastic leukemia Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 111:199–212PubMedCrossRefGoogle Scholar
  41. 41.
    Athale UH, Chan AKC (2003) Thrombosis in children with acute lymphoblastic leukemia Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 111:125–131PubMedCrossRefGoogle Scholar
  42. 42.
    Dietemann JL, Botelho C, Nogueira T, Vargas MI, Audibert C, Abu Eid M, Bogorin A, Bernardo R, Jacques C, Kremer S, Zollner G (2004) Imaging in acute toxic encephalopathy. J Neuroradiol 31:313–326PubMedCrossRefGoogle Scholar
  43. 43.
    Serkova NJ, Christians U, Benet LZ (2004) Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 4:97–107PubMedCrossRefGoogle Scholar
  44. 44.
    Casey SO, Ricardo C, Sampaio C, Truwit EM, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of Fluid-attenuated Inversion Recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21:1199–1206PubMedGoogle Scholar
  45. 45.
    Lamy C, Mas JL (2001) Reversible posterior leukoencephalopathy. A new syndrome or a new name for an old syndrome? Presse Med 30:915–920PubMedGoogle Scholar
  46. 46.
    Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123:1481–1494PubMedCrossRefGoogle Scholar
  47. 47.
    Mandrioli J, Cortelli P (2004) Patologie del sistema nervoso vegetativo. In: Sghirlanzoni A, Lauria G, Nardocci N, Pareyson D (eds) Terapia delle malattie neurologiche. Edi-Ermes, Milano, pp 309–328Google Scholar
  48. 48.
    Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A (2000) Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 47:104–109PubMedCrossRefGoogle Scholar
  49. 49.
    Uhm JH, Yung WK (1999) Neurologic complications of cancer therapy. Curr Treat Options Neurol 1:428–437PubMedGoogle Scholar
  50. 50.
    Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38:1832–1837PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2006

Authors and Affiliations

  • Alessandra Erbetta
    • 1
  • Giuseppe Lauria
    • 1
  • Angelo Sghirlanzoni
    • 1
  1. 1.Istituto Neurologico Carlo BestaMilano

Personalised recommendations